Sofosbuvir + Daclatasvir + Ribavirin — Competitive Intelligence Brief

Sofosbuvir + Daclatasvir + Ribavirin (Sofosbuvir + Daclatasvir + Ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination. Area: Infectious Disease / Virology.

phase 3 Direct-acting antiviral (DAA) combination NS5B polymerase, NS5A protein Infectious Disease / Virology Small molecule

Target snapshot

Sofosbuvir + Daclatasvir + Ribavirin (Sofosbuvir + Daclatasvir + Ribavirin) — Egyptian Liver Hospital. This combination inhibits hepatitis C virus replication by blocking the NS5B polymerase (sofosbuvir), NS5A protein (daclatasvir), and reducing viral load through ribavirin's direct antiviral activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sofosbuvir + Daclatasvir + Ribavirin TARGET	Sofosbuvir + Daclatasvir + Ribavirin	Egyptian Liver Hospital	phase 3	Direct-acting antiviral (DAA) combination	NS5B polymerase, NS5A protein
sofosbubir/velpatasvir/voxilaprevir	sofosbubir/velpatasvir/voxilaprevir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase, NS5A protein, NS3/4A protease
DCV 3DAA	DCV 3DAA	Bristol-Myers Squibb	phase 3	Direct-acting antiviral combination (protease inhibitor + polymerase inhibitor + NS5A inhibitor)	HCV NS3/4A protease, NS5B polymerase, NS5A protein
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase
Sofosbuvir and Velpatasvir	Sofosbuvir and Velpatasvir	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination class)

1. Massachusetts General Hospital · 3 drugs in this class
2. Egyptian Liver Hospital · 3 drugs in this class
3. Hannover Medical School · 2 drugs in this class
4. University of Maryland, Baltimore · 2 drugs in this class
5. Iran Hepatitis Network · 2 drugs in this class
6. Partners in Health · 2 drugs in this class
7. HaEmek Medical Center, Israel · 1 drug in this class
8. Almaza Military Fever Hospital · 1 drug in this class
9. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
10. Federal University of São Paulo · 1 drug in this class